Summary
Sanofi is a leader in developing vaccines for infectious diseases, and it has 73 manufacturing sites located in 32 countries. It’s portfolio that includes vaccines for polio, pertusis, Haemophilus influenzae type B, influenza, and meningitis, as well as travel vaccines. Sanofi’s COVID-19 response includes sarilumab, recombinant and mRNA vaccines.
Scope
Reasons to Buy
Sanofi is a leader in developing vaccines for infectious diseases, and it has 73 manufacturing sites located in 32 countries. It’s portfolio that includes vaccines for polio, pertusis, Haemophilus influenzae type B, influenza, and meningitis, as well as travel vaccines. Sanofi’s COVID-19 response includes sarilumab, recombinant and mRNA vaccines.
Scope
- This report gives an important expert analysis on how COVID-19 will affect Sanofi.
- Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Reasons to Buy
- An overview of how Sanofi will be affected by the COVID-19 pandemic.
Table of Contents
- Executive Summary
- Company Overview
- Key Stats
- SWOT Analysis
- Sales Overview
- Regional Analysis
- COVID-19 Spread vs. Location of Sanofi Trials
- COVID-19 vs. Non-COVID-19 Trials
- Reaction to COVID-19
- COVID-19 Vaccine
- mRNA Vaccine
- Sarilumab
- Hydroxychloroquine
- Insights Exclusive Intel: Sanofi
- Global Analyst Consensus Sales Forecast
- Upcoming Events
- Disrupted Clinical Trials
- Resumed Trials
- Recent Deal Activity
- Recruitment Trends
- Key Findings
Appendix
- Methodology
- About the Publisher
- Contacts
